Australia's most trusted
source of pharma news
Monday, 13 July 2026
Posted 13 July 2026 AM
A narcolepsy treatment, sodium oxybate, previously available only via special access, has been registered for use in Australia by REACH Pharmaceuticals, with the company currently considering a submission to the PBS.
The TGA has approved Reach’s SODIUM OXYBATE-REACH for the treatment of narcolepsy in adults, adolescents and children from the aged of seven years after accepting the Schedule 8 medicine for evaluation in March 2025 under orphan status.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.